Prevalence and treatment of mitochondrial diabetes in Southwest Finland
Abstract
Purpose: Diabetes mellitus (DM) is a common manifestation of mitochondrial disease, typically associated with the mitochondrial DNA (mtDNA) variant m.3243A>G. We investigated the clinical features, treatment, and epidemiology of mitochondrial DM in the region of Southwest Finland.
Methods: Electronic medical records at Turku University Hospital were searched for patients assigned ICD-10 codes E13.0-E13.9 during 2000-2022. Among 1004 screened individuals, nine patients with genetically confirmed mitochondrial diabetes were identified. Eight additional genetically confirmed patients were included from an ongoing mitochondrial disease research project, resulting in a cohort of 17 patients. The clinical characteristics and DM treatment of the patients were obtained from medical records.
Results: We identified 17 patients with mitochondrial DM. Mean age at diagnosis of DM was 35 years (range 11 to 60 years). Most patients with mitochondrial DM had hearing impairment (14/17). Insulin treatment was typically initiated 3.5 years after the diagnosis of DM. Only six (35%) patients had HbA1c below 7.0% (53 mmol/mol). The prevalence of mitochondrial DM in the region of Southwest Finland in the end of 2022 was 2.7/100,000 and annual incidence during the study period 0.14/100,000.
Conclusions: The onset of non-autoimmune diabetes in young adult age, particularly when associated with hearing impairment, suggests possible mitochondrial DM. Recognition of mitochondrial diabetes is essential…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,004 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.